Drug Database
IN

insulin glargine (Basalin / Changxiulin / Basugine)

✓ Approved

LG Chem Ltd. · INSR · Recombinant Proteins

What is insulin glargine?

insulin glargine is a recombinant proteins developed by LG Chem Ltd.. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesBasalin, Changxiulin, Basugine
CompanyLG Chem Ltd.
Drug ClassRecombinant Proteins, Polypeptide
Molecular TargetINSR
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, LG Chem Ltd.

Mechanism of Action

Molecular Targets

insulin glargine acts on 1 molecular target:

INSRinsulin receptor (CD220, HHF5)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

insulin glargine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 1 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedCardiovascular diabetology2026-07-25

Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.

Gessner Arne A, Kannenkeril Dennis D, Bosch Agnes A, Harazny Joanna M JM et al.

Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) provide cardiovascular and renal protection in both diabetic and non-diabetic patients at least in part independently of glycaemic control. Some underlying mechanisms for these clinically beneficial effects were suggested, but the picture is far from complete. In this study we aimed to apply untargeted metabolomics in order to identify new mechanistic leads. Plasma and 24-hour urine samples of 48 diabetic patients taken before and after 6 weeks of treatment from two prospective, randomized, double-blind, placebo-controlled, cross-over trials with dapagliflozin or empagliflozin were used. Additionally, plasma and urine samples of 24 diabetic patients from a prospective, randomized, controlled, parallel-arm, interventional, open-label, single centre study with either empagliflozin and linagliptin or metformin and insulin glargine for 12 weeks were used for confirmation. Changes of metabolite patterns in plasma and urine were determined by untargeted high-resolution mass spectrometry. Moreover, parameters of arterial stiffness and retinal vascular remodelling were correlated with treatment effects of the SGLT2 inhibitors on the modified nucleoside N4-acetylcytidine (ac4C), a potential biomarker for the activity of the enzyme N-acetyltransferase 10 (NAT10). In accordance with previously reported results treatment with SGLT2 inhibitors led to a reduction of glucose (log2fc: - 0.23, adj. p < 0.01) and uric acid (log2fc: - 0.23, adj. p < 0.001), while 3-hydroxybutyric acid (log2fc: 0.84, adj. p < 0.001) and 3-hydroxybutyrylcarnitine (log2fc: 0.57, adj. p < 0.001) were increased in plasma. As a new finding, plasma concentrations of ac4C were reduced (log2fc: - 0.32, adj. p < 0.001) by SGLT2 inhibitors but not by the non-SGLT2 inhibiting glucose lowering treatment. Reduction of urinary concentrations of ac4C corresponded to its reduction in plasma in groups treated with the SGLT2 inhibitors. Wall thickness of retinal arterioles and central systolic blood pressure were significantly correlated to ac4C in plasma. Treatment with dapagliflozin and empagliflozin reduced plasma concentrations of ac4C, which was correlated with parameters for vascular health. These exploratory findings may indicate inhibition of NAT10 activity as a potential contributor to the beneficial effects on cardiovascular and renal health by SGLT2 inhibitors. http://www. gov : NCT02383238, NCT02471963, NCT02752113.

PMID 42498959
Read full article →
PubMedJournal of environmental sciences (China)2026-07-25

Role of macrophage NLRP3 inflammasome activation in real-ambient particulate matter-induced abnormal hepatic glucose metabolism.

Wu Dong D, Zhang Zhen Z, Chen Sixin S, Chen Haoran H et al.

Evidence regarding the effects of particulate matter (PM) exposure on hepatic glucose metabolism and insulin resistance is limited, and its mechanisms remain unclear. Macrophages, as key regulators of the liver microenvironment, may mediate PM-induced metabolic processes. This study used an individually ventilated cage (IVC)-based real-ambient PM exposure system mouse model, co-cultured macrophages and hepatocytes, and NOD-like receptor protein 3 (Nlrp3)-knockdown model to investigate the impact of macrophages on hepatic insulin resistance (IR) and glucose metabolism under PM exposure. Our findings revealed that glycogen storage was impaired, insulin signaling was suppressed, the mRNA expression of glucose metabolism-related genes was altered, and the number of macrophages increased in the mouse liver after 15 weeks of PM exposure. Additionally, PM exposed mice exhibited reduced glucose tolerance and insulin sensitivity. In the transwell co-culture model, macrophages exposed to PM for 72 h exhibited NLRP3 inflammasome activation and IL-1β release, which were associated with lysosomal damage and cathepsin B release, accompanied by inhibition of insulin signaling and abnormal expression of glucose metabolism-related genes in hepatocytes. In vitro inhibition of NLRP3 and in vivo knockdown of Nlrp3 significantly attenuated these effects of PM exposure. Additionally, IL-1β inhibition improved glucose metabolism abnormalities. These findings reflect specific effects on insulin signaling and glucose metabolism mediated by the NLRP3 inflammasome or IL-1β. These results suggest that PM exposure leading to macrophage NLRP3 inflammasome activation and IL-1β release is an important cause of abnormal hepatic glucose metabolism, providing new insights into the underlying mechanisms of PM-related hepatic glucose metabolism and IR.

PMID 42498412
Read full article →
PubMedRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia2026-07-25

Metformin + Insulin vs. Insulin for GDM and T2DM during pregnancy: systematic review and meta-analysis.

Hallack Christiano C, Nogueira Bernardo Vieira BV, Bomfim Maressa M, Meireles Nathália N et al.

Evaluate the effectiveness and safety of adding metformin to insulin (M+I) versus insulin alone for pregnant women with type 2 diabetes mellitus (T2DM) or gestational diabetes mellitus (GDM), focusing on stillbirth as the primary outcome. PubMed, Embase, and Cochrane Central were searched. No date limits. Last search: January 2025. Randomized clinical trials including women with T2DM or GDM were eligible. Trials restricted to type 1 diabetes were excluded. Two reviewers extracted maternal and neonatal outcomes and assessed risk of bias with the Cochrane RoB 2 tool. Evidence certainty was graded using GRADE. Data were pooled with random-effects models and reported as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals. Nine RCTs (2,420 women) were included, most with GDM and some with T2DM. Moderate-quality evidence indicated reduced stillbirth risk with M+I (6 RCTs, 2,196 participants; RR 0.36, 95% CI 0.14-0.90; NNT 111). Low-quality evidence suggested lower risks of gestational hypertension (4 RCTs; RR 0.68, 95% CI 0.48-0.97) and neonatal hypoglycemia (7 RCTs; RR 0.49, 95% CI 0.30-0.80). No significant differences were found for cesarean section, preterm delivery, or other neonatal outcomes. Heterogeneity, baseline imbalances, and small samples limited certainty. M+I may reduce stillbirth and some adverse outcomes compared with insulin alone, but most evidence remains low certainty. Further high-quality RCTs are needed.Registered in PROSPERO: CRD42024617330.

PMID 42500179
Read full article →
PubMedMetabolism: clinical and experimental2026-07-25

Differential mirroring between in vivo insulin secretion and ex vivo islet function in individuals with and without diabetes.

Di Giuseppe Gianfranco G, Gliozzo Giulia G, Carciero Lorenzo L, Puzzangara Maria Carmen MC et al.

Insulin secretion measured in vivo reflects the integrated output of pancreatic islets within a multi-organ regulatory network, whereas ex vivo stimulation of isolated human islets captures intrinsic, islet-autonomous secretory competence. Whether these two levels of β cell function mirror each other in humans remains unclear. We studied 63 individuals undergoing partial pancreatectomy who underwent preoperative OGTT with model-based assessment of β cell function and provided pancreatic tissue for ex vivo islet isolation and glucose stimulation. Ex vivo function was quantified as the stimulation index at 16.7 mmol/L glucose (SI16.7) and related to in vivo indices of insulin secretion. SI16.7 was reduced in islet from people with T2D but showed marked inter-individual variability with overlapping distributions between individuals with and without T2D. In non-diabetic individuals, no significant associations were detected between SI16.7 and OGTT-derived indices. In contrast, in people with T2D, SI16.7 was positively associated with multiple measures of glucose-driven insulin secretion and inversely with potentiation. In multivariable analysis, a composite index of intrinsic glucose-dependent β cell competence remained independently related to SI16.7. These findings indicate that a direct correspondence between systemic β cell function and intrinsic islet secretory capacity emerges only in T2D. This state-dependent alignment suggests that loss of network-mediated regulation may unmasks islet-intrinsic defects, allowing ex vivo islet performance to better reflect in vivo insulin secretion and supporting integrated in vivo-ex vivo phenotyping as a tool for functional stratification of T2D.

PMID 42498076
Read full article →
PubMedMedicine2026-07-25

Perioperative nursing care for a patient undergoing image-guided planned autologous islet transplantation after total pancreatectomy: A case report.

Yang Jianwen J, Qi Xuefeng X, Xu Qin Q, Qian Weiming W

Total pancreatectomy (TP) often leads to insulin-deficient diabetes, including unstable "brittle diabetes." Autologous islet transplantation during or after TP can prevent or treat diabetes by reinfusing functional islets into the portal vein. This case report details the perioperative nursing strategies for a patient undergoing image-guided planned autologous islet transplantation following TP. A 64-year-old male with pancreatic cancer, type 2 diabetes, and hypertension underwent TP and initial autologous islet transplantation but required a second transplantation due to poor graft function. Preoperatively, he exhibited fluctuating blood glucose (8.9-14.5 mmol/L) and anxiety about surgical outcomes. The patient was diagnosed with recurrent pancreatic cancer post-TP and chemotherapy, compounded by insulin-dependent diabetes and suboptimal islet function necessitating secondary transplantation. A multidisciplinary approach included meticulous preoperative islet quality control, intraoperative portal vein catheterization under ultrasound guidance, and dynamic monitoring of portal pressure. Postoperative care featured anticoagulation (heparin/low-molecular-weight heparin), glycemic management via insulin micropump, and thromboprophylaxis using intermittent pneumatic compression. Psychological support and preoperative education alleviated patient anxiety. Posttransplantation, blood glucose stabilized (3.9-7.7 mmol/L), enabling discontinuation of exogenous insulin. The patient was discharged on day 18 without complications such as thrombosis or hemorrhage. Multidisciplinary collaboration, tailored nursing interventions, and rigorous complication prevention ensured successful outcomes. This case highlights the critical role of structured perioperative care in achieving insulin independence after complex islet transplantation.

PMID 42499104
Read full article →
PubMedMolecular and cellular endocrinology2026-07-25

Gut Microbiota Contributes to Protection Against High-Fat Diet- Induced Insulin Resistance in iNOS Knockout Mice.

Zanotto Tamires M TM, Santos Andrey A, Vecina Juliana F JF, Quaresma Paula G F PGF et al.

Inducible nitric oxide synthase (iNOS) is activated in obesity and is involved in the regulation of cellular pathways, including the unfolded protein response and insulin signaling. We previously showed that iNOS deficiency is associated with reduced obesity-induced insulin resistance (IR), particularly in skeletal muscle, in iNOS knockout (iNOS KO) mice fed a high-fat diet (HFD). However, the mechanisms underlying protection against HFD-induced IR in iNOS KO mice remain incompletely understood. Several studies have reported associations between gut microbiota composition and metabolic outcomes, including body weight regulation and insulin resistance, with differences observed between lean and obese subjects. However, the potential contribution of the gut microbiota to the metabolic phenotype observed in iNOS KO mice has not been fully investigated. To address this question, we assessed glucose homeostasis, adipose tissue inflammation, gut microbiota composition, and intestinal barrier integrity. Fecal microbiota transfer (FMT) experiments were also performed between HFD-fed iNOS KO and C57BL/6J mice in both directions. HFD-fed iNOS KO mice exhibited reduced adipose tissue inflammation, characterized by decreased numbers of mast cells and pro-inflammatory M1 macrophages, together with increased numbers of anti-inflammatory M2 macrophages, compared with HFD-fed C57BL/6J mice. The gut microbiota profile of HFD-fed iNOS KO mice was associated with increased expression of genes related to intestinal tight junction integrity. Fecal microbiota transfer from HFD-fed iNOS KO mice was associated with improved glucose tolerance, enhanced insulin sensitivity, and increased expression of genes related to intestinal tight junction integrity in recipient mice. These findings suggest that gut microbiota contributes, at least in part, to the protection against HFD-induced IR in iNOS KO mice and support the potential of targeting gut microbiota as a therapeutic strategy to improve metabolic disturbances.

PMID 42498211
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about insulin glargine